PCSK9 inhibition tied to decreased psoriasis risk
Inhibition of the proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway appears to be causally associated with a lower risk of psoriasis, regardless of the concentration levels of circulating low-density lipoprotein (LDL), according a two-sample Mendelian randomization study.
Long-term OLE boosts potential of remibrutinib for CSU
In the 52-week open-label extension (OLE) of a phase IIb study presented at AAAAI 2023, the BTK* inhibitor remibrutinib demonstrated sustained efficacy and a favourable safety profile for the treatment of chronic spontaneous urticaria (CSU).
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in